LNK mutation studies in blast-phase myeloproliferative neoplasms and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations

Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias

(2010) O. Abdel-Wahab et al.   CANCER RESEARCH

Lnk constrains myeloproliferative diseases in mice

(2010) Alexey Bersenev et al.   JOURNAL OF CLINICAL INVESTIGATION

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

(2009) Sigal Gery et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status—clinical correlates in a study of 226 consecutive patients

(2009) A Pardanani et al.   LEUKEMIA

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

(2009) A Tefferi et al.   LEUKEMIA

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

(2008) A M Vannucchi et al.   LEUKEMIA